Medtronic Plc's Customers Performance
MDT
|
MDT's Source of Revenues |
Medtronic Plc's Corporate Customers have recorded an advance in their cost of revenue by 8.92 % in the 4 quarter 2023 year on year, sequentially costs of revenue grew by 33.76 %. During the corresponding time, Medtronic Plc recorded revenue increase by 4.68 % year on year, sequentially revenue grew by 1.32 %. While revenue at the Medtronic Plc's corporate clients recorded rose by 9.16 % year on year, sequentially revenue grew by 26.07 %.
• List of MDT Customers
|
|
Medtronic Plc's Customers have recorded an advance in their cost of revenue by 8.92 % in the 4 quarter 2023 year on year, sequentially costs of revenue grew by 33.76 %, for the same period Medtronic Plc recorded revenue increase by 4.68 % year on year, sequentially revenue grew by 1.32 %.
• List of MDT Customers
Select the Relationship:
|
|
Select the Category:
|
|
Customers Net Income fell in Q4 by |
Customers Net margin fell to % |
-1.34 % |
2.96 % |
Medtronic Plc's Comment on Sales, Marketing and Customers
We sell most of our medical devices through direct sales representatives in
the U.S. and a combination of direct sales representatives and independent distributors
in markets outside the U.S. The three largest markets for our medical devices
are the U.S., Western Europe, and Japan. Emerging markets are an area of increasing
focus and opportunity as we believe they remain underpenetrated.
Our marketing and sales strategy is focused on rapid, cost-effective delivery
of high-quality products to a diverse group of customers worldwide - including
physicians, hospitals, other medical institutions, and group purchasing organizations.
To achieve this objective, we organize our marketing and sales teams around
physician specialties. This focus enables us to develop highly knowledgeable
and dedicated sales representatives who are able to foster strong relationships
with physicians and other customers and enhance our ability to cross-sell complementary
products. We believe that we maintain excellent working relationships with physicians
and others in the medical industry that enable us to gain a detailed understanding
of therapeutic and diagnostic developments, trends, and emerging opportunities
and respond quickly to the changing needs of physicians and patients. We attempt
to enhance our presence in the medical community through active participation
in medical meetings and by conducting comprehensive training and educational
activities. We believe that these activities contribute to physician expertise.
In keeping with the increased emphasis on cost-effectiveness in health care
delivery, the current trend among hospitals and other customers of medical device
manufacturers is to consolidate into larger purchasing groups to enhance purchasing
power. As a result, transactions with customers have become increasingly significant
and more complex. This enhanced purchasing power may also lead to pressure on
pricing and increased use of preferred vendors. Our customer base continues
to evolve to reflect such economic changes across the geographic markets we
serve. We are not dependent on any single customer for more than 10 percent
of our total net sales.
News about Medtronic Plc Contracts |
FDA Approves Medtronic's Advanced Percept RC Neurostimulator with Exclusive BrainSense Technology: Revolutionizing Deep Brain StimulationIn a breakthrough development, the FDA has granted approval to Medtronic for its latest innovation - the Percept RC neurostimulator. Esteemed as the first and only deep brain stimulation system with sensing, directionality, and advanced programming, the Percept RC is set to revolutionize the treatment of neurological disorders. Medtronic plc, a global leader in healthcare technology, unveiled this revolutionary device on January 8, 2024.The Percept RC neurostimulator, equipped with exclusive BrainSense technology, marks a significant leap forward in the field of deep brain ...
|
Medtronic Plc's Comment on Sales, Marketing and Customers
We sell most of our medical devices through direct sales representatives in
the U.S. and a combination of direct sales representatives and independent distributors
in markets outside the U.S. The three largest markets for our medical devices
are the U.S., Western Europe, and Japan. Emerging markets are an area of increasing
focus and opportunity as we believe they remain underpenetrated.
Our marketing and sales strategy is focused on rapid, cost-effective delivery
of high-quality products to a diverse group of customers worldwide - including
physicians, hospitals, other medical institutions, and group purchasing organizations.
To achieve this objective, we organize our marketing and sales teams around
physician specialties. This focus enables us to develop highly knowledgeable
and dedicated sales representatives who are able to foster strong relationships
with physicians and other customers and enhance our ability to cross-sell complementary
products. We believe that we maintain excellent working relationships with physicians
and others in the medical industry that enable us to gain a detailed understanding
of therapeutic and diagnostic developments, trends, and emerging opportunities
and respond quickly to the changing needs of physicians and patients. We attempt
to enhance our presence in the medical community through active participation
in medical meetings and by conducting comprehensive training and educational
activities. We believe that these activities contribute to physician expertise.
In keeping with the increased emphasis on cost-effectiveness in health care
delivery, the current trend among hospitals and other customers of medical device
manufacturers is to consolidate into larger purchasing groups to enhance purchasing
power. As a result, transactions with customers have become increasingly significant
and more complex. This enhanced purchasing power may also lead to pressure on
pricing and increased use of preferred vendors. Our customer base continues
to evolve to reflect such economic changes across the geographic markets we
serve. We are not dependent on any single customer for more than 10 percent
of our total net sales.
MDT's vs. Customers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
COMPANY NAME |
MARKET CAP |
REVENUES |
INCOME |
EMPLOYEES |
Medtronic Plc |
111,410.02 |
32,319.00 |
4,234.00 |
95,000 |
Quest Diagnostics Inc |
14,610.36 |
9,252.00 |
908.00 |
49,000 |
Neogenomics Inc |
1,846.07 |
591.60 |
-87.97 |
2,000 |
Cvs Health Corporation |
100,037.72 |
357,776.00 |
8,368.00 |
300,000 |
Davita Inc |
12,770.10 |
12,140.15 |
956.98 |
69,000 |
Fresenius Medical Care Ag |
5,586.59 |
21,788.05 |
820.35 |
1,254 |
Heartland Media Acquisition Corp |
202.86 |
0.00 |
4.01 |
0 |
Rite Aid Corp |
35.86 |
23,475.49 |
-1,635.20 |
50,000 |
Tenet Healthcare Corp |
10,741.19 |
20,548.00 |
1,311.00 |
108,000 |
SUBTOTAL |
145,830.75 |
445,571.29 |
10,645.17 |
579,254 |
|